Metformin, the universal first-line treatment for type 2 diabetes, exerts its therapeutic glucose-lowering effects by inhibiting hepatic gluconeogenesis. However, the primary molecular mechanism of this biguanide remains unclear, though it has been suggested to act, at least partially, by mitochondrial complex I inhibition. Here we show that clinically relevant concentrations of plasma metformin achieved by acute intravenous, acute intraportal or chronic oral administration in awake normal and diabetic rats inhibit gluconeogenesis from lactate and glycerol but not from pyruvate and alanine, implicating an increased cytosolic redox state in mediating metformin's antihyperglycemic effect. All of these effects occurred independently of complex I inhibition, evidenced by unaltered hepatic energy charge and citrate synthase flux. Normalizing the cytosolic redox state by infusion of methylene blue or substrates that contribute to gluconeogenesis independently of the cytosolic redox state abrogated metformin-mediated inhibition of gluconeogenesis in vivo. Additionally, in mice expressing constitutively active acetyl-CoA carboxylase, metformin acutely decreased hepatic glucose production and increased the hepatic cytosolic redox state without altering hepatic triglyceride content or gluconeogenic enzyme expression. These studies demonstrate that metformin, at clinically relevant plasma concentrations, inhibits hepatic gluconeogenesis in a redox-dependent manner independently of reductions in citrate synthase flux, hepatic nucleotide concentrations, acetyl-CoA carboxylase activity, or gluconeogenic enzyme protein expression.
I t is well established that metformin, albeit at millimolar concentrations, will inhibit mitochondrial complex I activity, and it has since been generally postulated that its potent antidiabetic effects occur through this mechanism 1,2 . Following from this mechanism, it has been described that by diminishing electron transport chain activity, metformin decreases energy charge (ratio of ATP concentration to ADP concentration, [ATP]: [ADP] , and ratio of ATP concentration to AMP concentration, [ATP]:[AMP]) 1,2 , thus increasing AMP kinase (AMPK)-Thr172 phosphorylation, promoting transcriptional downregulation of gluconeogenic enzymes 3, 4 and inhibiting acetyl-CoA carboxylase 1 (ACC1) and ACC2 activities 5 . Complex I inhibition and AMPK activation are possibly the most widely studied outcomes of metformin treatment, and they are invoked as the mechanism of metformin-mediated inhibition of hepatic lipogenesis, decrease in triglyceride accumulation, and increase in hepatic insulin sensitivity [6] [7] [8] [9] [10] . Additional studies have tested the hypothesis that metformin-mediated increases in AMP concentration can allosterically modulate key metabolic pathways to increase glycolytic flux over gluconeogenic flux 11 , inhibit glucagon-mediated transcription of gluconeogenic genes 12 , or inhibit glucagon action via phosphodiesterase 4 (PDE4) 13 . Though compelling, these mechanisms are often delineated in the context of suprapharmacological metformin dosing. They are also challenged by data showing that metformin, at clinically relevant plasma concentrations, does not appreciably alter energy charge or AMP concentration 14, 15 and is capable of exerting its therapeutic effects in the absence of AMPK expression 11 . It is therefore plausible that there are critical actions of metformin independent of major alterations in adenine nucleotide concentration or AMPK action.
We previously demonstrated that metformin inhibits hepatic gluconeogenesis by functionally decreasing mitochondrial glycerol-3-phosphate dehydrogenase (GPD2) activity 15 . This enzyme is a key component of the α -glycerophosphate shuttle, which is one of two shuttle systems required to transfer reducing equivalents from the cytosol to the mitochondria [16] [17] [18] , altering cytosolic redox balance and suppressing hepatic gluconeogenesis 15 . In our previous work, we showed that loss of hepatic GPD2 expression phenocopies metformin treatment. Furthermore, we demonstrated that metformin's ability to decrease plasma glucose concentrations and hepatic glucose production is abrogated when hepatic GPD2 protein expression is ablated genetically in GPD2 knockout mice or transiently in rats treated with a GPD2 antisense oligonucleotide 15 . In the present study, we use 13 C positional isotopomer tracer analyses to follow carbon flux in vivo to specifically ascertain that metformin, via inhibition of GPD2, targets hepatocellular redox metabolism to achieve its therapeutic effect in awake, unrestrained diabetic and nondiabetic rats.
Results
Redox regulation of gluconeogenesis varies with the carbon source. In particular, a more reduced cytosol (i.e., an increased cytosolic Metformin inhibits gluconeogenesis via a redox-dependent mechanism in vivo [NADH] :[NAD + ] ratio) inhibits gluconeogenesis from lactate and glycerol 19, 20 but not from alanine and pyruvate 21, 22 . The key difference between these substrates is the increased sensitivity of lactate and glycerol to a reduced cytosol and thus an increased cytosolic [NADH]:[NAD + ] ratio, as these substrates, unlike pyruvate or alanine, will themselves reduce the cytosol ( Supplementary Fig. 1a ). Glycerol, which can contribute to approximately 20-30% of hepatic gluconeogenesis under certain conditions 23, 24 , enters gluconeogenesis via the α -glycerophosphate shuttle and reduces the cytosol if processed by cytosolic glycerol-3-phosphate dehydrogenase (GPD1) ( Supplementary Fig. 1b ).
Of note, metformin decreased glucose production only from lactate and glycerol in vitro, reflecting the expected metabolic outcome of cytosolic redox modulation as opposed to generalized inhibition of gluconeogenesis that may result from downregulating the gluconeogenic transcriptional program 15 . Further evidence for a redoxmodulatory effect of metformin is provided by the observation that GPD2 inhibition by metformin increased liver cytosolic redox, reflected by a [lactate]:[pyruvate] ratio > 10, which represses hepatic gluconeogenesis 20, 25 . In isolated primary hepatocytes, metformin suppressed hepatic glucose production from gluconeogenic substrates that depend on cytosolic NADH (lactate and glycerol), but not from gluconeogenic substrates independent of cytosolic NADH (dihydroxyacetone (DHA), alanine, pyruvate) ( Supplementary  Fig. 1c ). In contrast, both the pyruvate carboxylase (PC) inhibitor phenylacetate and the cytosolic phosphoenolpyruvate carboxykinase (PEPCK-C) inhibitor 3-mercaptopicolinic acid did not exhibit a substrate-selective pattern of inhibition. The substrate-specific effect observed with metformin treatment is a hallmark of a redoxmediated inhibition of gluconeogenesis and distinguishes this mechanism from all other proposed mechanisms for metformin inhibition of hepatic gluconeogenesis 2, 3, [5] [6] [7] [8] [9] [10] [11] [12] [13] . Impact of acute intravenous metformin treatment on substratespecific contributions to hepatic gluconeogenesis. To evaluate the importance of redox modulation to the therapeutic effects of metformin in vivo, we measured the effect of acute intravenous (i.v.) metformin treatment on the specific contributions of lactate and alanine to gluconeogenesis in awake Sprague Dawley (SD) rats. We previously demonstrated that an acute i.v. dose of metformin at 50 mg per kg body weight (mg kg -1 ) can achieve plasma concentrations of 25-50 μ M, approximating plasma concentrations observed in individuals with type 2 diabetes (T2D) administered an acute oral dose (1 g) of metformin, and comparable to plasma concentrations seen in individuals with T2D being treated with chronic oral metformin dosing (1 g twice per day) ( Supplementary Fig. 2) 26 . In contrast, prior studies in rats and mice have used very high parenterally administered doses of ≥ 200 mg kg -1 metformin 2,3,12,13,27-29 , which elicit peak plasma concentrations of ~1,200 μ M 15 that are suprapharmacological. Doses that result in millimolar plasma metformin concentrations may have effects on hepatic metabolism (e.g., complex I inhibition, etc.) that are not clinically relevant to the primary effects of metformin in individuals with T2D. Therefore, in order to achieve clinically relevant plasma metformin concentrations and avoid suprapharmacological effects, all acute intravenous (i.v.) and intraportal vein studies were performed using 50 mg kg -1 metformin.
By using either a [3-13 C]lactate or [3-13 C]alanine tracer we were able to track 13 C carbons, which would be scrambled to the 1, 2, 5, and 6 carbon positions of glucose ([1-13 C], [2-13 C], [5-13 C] , or [6-13 C]glucose) through hepatic gluconeogenesis. The fraction of total liver [1-13 C], [2-13 C], [5-13 C] , and [6-13 C]glucose over total liver [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] C]substrate (lactate or alanine) provides the relative contribution of that substrate to gluconeogenesis. Entry of the label from [3-13 C]lactate is influenced by redox state because of the cytosolic NADH-producing lactate dehydrogenase step ( Fig. 1a) , whereas [3-13 C]alanine labels glucose independently of cytosolic redox modulation ( Fig. 1b ). During both tracer infusion studies, we observed that metformin acutely decreased plasma glucose concentrations in awake, unrestrained SD rats that were fasted for 24 h and depleted of hepatic glycogen (Fig. 1c ). This decrease was accompanied by a threefold-higher liver [lactate]:[pyruvate] ratio, representative of an increase in the cytosolic redox state ( Fig. 1d and Supplementary Fig. 3a,b ), and a decrease in the hepatic mitochondrial redox state, represented by a lower [β -hydroxybutyrate]:[acetoacetate] ratio ( Fig. 1e and Supplementary Fig. 3c,d) . Although acute i.v. metformin treatment suppressed endogenous glucose production (EGP) during both studies (Fig. 1f ), the contribution of alanine to hepatic gluconeogenesis was unchanged, evidenced by the absence of any impact on the [1-13 C], [2-13 C], [5-13 C] , [6-13 C] glucose: [3-13 C] alanine ratio by metformin as compared to saline (denoted by a metformin:saline ratio of ~1). Metformin specifically decreased the contribution of lactate to hepatic glucose production, evidenced by a metformin:saline ratio < 1 for the [1-13 C], [2-13 C], [5-13 C] , [6-13 C] glucose and [3-13 C]lactate fractions ( Fig. 1g and Supplementary Fig. 3e ). This substrate-selective effect of metformin on lactate's contribution to glucose production in these hepatic-glycogen-depleted rats reveals that metformin modulates the redox state to inhibit hepatic gluconeogenesis in vivo. The observations that acute metformin treatment increased plasma glycerol and led to higher liver glycerol-3-phosphate (G-3-P) concentrations ( Supplementary Fig. 3f ,g) are consistent with metformin's potential mechanism of action to inhibit GPD2 activity, which in turn would decrease glycerol conversion to glucose. Metformin-induced reductions in plasma glucose concentration and inhibition of EGP were independent of changes in hepatic triglyceride and glycogen content ( Supplementary Fig. 3h ,i), indicating that the acute effect of metformin, under these conditions and at clinically relevant plasma concentrations, is to suppress hepatic gluconeogenesis 30, 31 and is not mechanistically explained by increased hepatic fat oxidation 5, 29 or by decreased net hepatic glycogenolysis 32, 33 . Furthermore, expression of hepatic glucose-6-phosphatase (G6Pase) protein was unchanged, whereas hepatic PEPCK-C and PC proteins were higher and phosphorylation of cAMP response element-binding protein (CREB) at Ser133, the activated form of the key gluconeogenic transcriptional regulator, was higher ( Supplementary Fig. 4a-d ). These findings dissociate metformin's acute therapeutic effect from the transcriptional regulation of hepatic gluconeogenesis 3, 12 .
We found that hepatic AMPK was activated by acute metformin treatment, though surprisingly, this did not translate to a detectable downstream effect on the AMPK substrate ACC, since ACC phosphorylation by AMPK is a measure of AMPK activation but was unchanged ( Supplementary Fig. 4e ,f). Taken together, these data demonstrate that metformin suppresses hepatic gluconeogenesis from glycerol and lactate but not from alanine in vivo, providing strong evidence that metformin inhibits gluconeogenesis by inhibition of GPD2 through direct or indirect means resulting in modulation of the hepatic cytosolic and mitochondrial redox states.
In order to determine whether redox-mediated suppression of hepatic gluconeogenesis is a relevant mechanism of metformin action in diabetes, we also performed [3-13 C]lactate and [3-13 C] alanine tracer infusion studies in a well-established rodent model of T2D, the Zucker Diabetic Fatty (ZDF) rat. Fasting plasma glucose concentrations of these ZDF rats were markedly higher than those of SD rats, and acute metformin treatment induced a large reduction (> 220 mg dL -1 ) in plasma glucose concentrations ( Fig. 2a ). Hepatic cytosolic redox state was higher ( Fig. 2b and Supplementary Fig. 5a ,b) and mitochondrial redox state was lower with metformin treatment ( Fig. 2c and Supplementary  Fig. 5c,d ). These alterations in redox state were concomitant with a > 50% lower EGP rate in ZDF rats treated with metformin rather than saline ( Fig. 2d ). As observed in SD rats, metformin did not impact alanine contributions to hepatic gluconeogenesis but did specifically inhibit lactate contributions, assessed using the metformin:saline ratio of the liver [1-13 C], [2-13 C], [5-13 C] , [6-13 C] glucose:[3-13 C]lactate enrichment following infusion of [3-13 C] lactate ( Fig. 2e and Supplementary Fig. 5e ). Plasma glycerol and liver G-3-P concentrations were both increased ( Supplementary   Fig. 5f ,g), again implicating inhibition of GPD2 as the target of acute metformin action decreasing hepatic gluconeogenesis in this rat model of poorly controlled T2D.
Metformin-mediated inhibition of EGP in the ZDF rats was also dissociated from changes in liver triglyceride or glycogen content ( Supplementary Fig. 5h ,i) and was independent of alterations in the protein expression of key gluconeogenic enzymes ( Supplementary  Fig. 6a-d ). Hepatic AMPK was activated, though again there was surprisingly no detectable change in the phosphorylation state of ACC ( Supplementary Fig. 6e ,f).
Effect of acute i.v. metformin on EGP and lipid metabolism in ACC double knock-in mice.
In light of the possibility that ACC phosphorylation is required for metformin's glucose-lowering effects 5 , we examined the effect of acute metformin treatment in a double knock-in (DKI) mouse model with alanine mutations at Ser79 of ACC1 and Ser212 of ACC2 (ACC DKI mice) that has previously been described 5 . Acute i.v. metformin treatment decreased plasma glucose concentrations ( Fig. 3a) , increased hepatic cytosolic redox state and decreased the mitochondrial redox state (Fig. 3b ,c) in both the ACC DKI mice and wild-type (WT) mice. EGP was also significantly decreased in both ACC DKI and WT mice (Fig. 3d ). The plasma-glucose-lowering effect of metformin we observed in both WT and ACC DKI mice is consistent with previous data showing that both chow-and high-fat diet (HFD)-fed ACC DKI mice manifested a reduction in plasma glucose concentrations in response to a high dose of metformin (200 mg kg -1 , intraperitoneal (i.p.)) 5 . Though the prior study reported that 50 mg kg -1 i.p. metformin did not impact blood glucose concentration in ACC DKI mice, basal EGP is a more sensitive indicator of metformin action, and this parameter was not measured in this prior study in response to acute metformin treatment 5 .
As anticipated from data showing that metformin does not decrease hepatic triglyceride content in individuals with nonalcoholic fatty liver disease (NAFLD) [34] [35] [36] and does not impact fatty acid oxidation and lipid metabolism in individuals with T2D 37 , we observed no effect on liver triglyceride content in either ACC DKI or WT mice following treatment with acute metformin, though liver triglycerides were elevated in ACC DKI mice compared to WT, as previously reported 5 (Fig. 3e ). Although activating phosphorylation of AMPK at Thr172 was increased, there was no effect on ACC phosphorylation in either WT or ACC DKI mice ( Fig. 3f ,g). Finally, while metformin treatment of both WT and ACC DKI mice lowered plasma glucose concentrations and EGP, it did not elicit changes in G6Pase, pyruvate carboxylase or PEPCK-C protein expression ( Fig. 3h-j) . These data demonstrate that metformin's ability to acutely suppress hepatic glucose production at clinically relevant plasma concentrations in vivo is not dependent on ACC activity or reductions in hepatic gluconeogenic enzyme expression.
Abrogation of acute intravenous metformin-mediated effects by methylene blue and pyruvate and DHA infusion in normal SD rats.
Given that metformin treatment inhibits hepatic gluconeogenesis from redox-modulating substrates in normal SD and ZDF rats, we hypothesized that infusion of pyruvate and DHA would acutely abrogate the glucose lowering effects of metformin while infusion of lactate and glycerol would have no effect on metformin action in SD rats. Consistent with this hypothesis, infusion of pyruvate and DHA abolished metformin-induced reductions in plasma glucose concentrations, but infusion of lactate and glycerol did not block metformin's glucose-lowering effect (Fig. 4a ). Concomitantly, the liver cytosolic redox state was lower following pyruvate and DHA infusion, and there was no effect on the mitochondrial redox state (Fig. 4b,c ). Hepatic G-3-P concentrations were maintained with pyruvate and DHA treatment but were markedly elevated with infusion of lactate and glycerol ( Fig. 4d ). This is likely due to the impediment of excess glycerol substrate from entering gluconeogenesis because of inhibition of GPD2 by metformin. Finally, EGP was elevated in metformin-treated rats infused with pyruvate and DHA ( Fig. 4e ), but not in metformin-treated rats infused with lactate and glycerol. Taken together, these results confirm that metformin increases the cytosolic redox state and, in this manner, inhibits lactate and glycerol conversion to glucose, with no effect on pyruvate and DHA contributions to hepatic gluconeogenesis.
To further examine the modulation of redox state by metformin, we infused methylene blue (MB) intravenously into SD rats acutely treated with metformin. MB has been shown to influence the cytosolic [ 10 min following acute i.v. metformin infusion abrogated metformin's ability to lower fasting plasma glucose concentrations (Fig. 4f ), alter liver cytoplasmic ( Fig. 4g ) and mitochondrial ( Fig. 4h) redox ratios, and inhibit EGP (Fig. 4i ). Taken together, these data demonstrate that by preventing metformin-mediated increases in the cytoplasmic redox state, MB abrogated metformin's glucose-lowering effect. These findings offer further evidence that metformin inhibits hepatic gluconeogenesis by increasing the cytoplasmic redox state. Although it has been suggested that the malate-aspartate shuttle should compensate for any reductions in the α -glycerophosphate shuttle activity 8, 39, 40 , the increases in cytosolic redox state and decreases in mitochondrial redox state observed with both acute and chronic metformin treatment and with genetic knockdown of mitochondrial glycerol phosphate dehydrogenase 15 clearly show that this is not the case. Furthermore, the contribution to hepatic gluconeogenesis from glycerol, which is increased in individuals with T2D 41, 42 , is uniquely impacted by α -glycerophosphate shuttle inhibition. This effect of metformin would not be reversed by enhanced malate-aspartate shuttling.
Acute intraportal vein infusion of low-dose metformin decreases plasma glucose and inhibits EGP by modulating hepatic redox
state. It has also been postulated that the acute glucose-lowering effects of metformin are primarily via gastrointestinal effects and that direct effects on hepatic metabolism are seen with chronic treatment 27, 43 . However, this hypothesis conflicts with studies in portal vein-strictured rats in which orally administered metformin had no effect on plasma glucose concentration 44 . Furthermore, it was shown using [ 11 C]metformin tracer in humans that, whether administered intravenously or orally, the drug is primarily taken up by the liver, and that intestinal uptake is low 45 . Also challenging a primarily gastrointestinal effect is a study showing that metforminstimulated GLP-1 secretion was insufficient to mediate metformin's acute glucose-lowering effect in individuals with T2D 46 .
To provide further evidence that metformin's inhibition of hepatic gluconeogenesis directly affects the liver and is independent of effects in the gut or on gut microbiota, we performed studies administering metformin via infusion through the portal vein. Acute infusion of 50 mg kg -1 metformin into the portal vein of normal SD rats gave rise to peak plasma metformin concentrations of ~130 μ M and hepatic metformin concentrations of ~25 μ M at 2 h following administration ( Supplementary Fig. 7 ), comparable to the therapeutic range observed in individuals with T2D treated with metformin 47 . For subsequent portal vein infusion studies, we used a well-established rat model of T2D exhibiting both insulin resistance and partial β -cell failure: streptozotocin-nicotinamide (STZ)-treated SD rats fed a HFD for 4 weeks. Similar to systemic i.v. metformin treatment, acute treatment with 50 mg kg -1 metformin via the portal vein in this rodent model of T2D acutely decreased plasma glucose concentrations within 30 min and sustained this decrease in plasma glucose concentrations over 2 h (Fig. 5a ). Metformin administered through the portal vein led to a decrease in EGP rates by ~25% at 2 h (Fig. 5b) . These data demonstrate that infusion of metformin via the portal vein decreases plasma glucose and inhibits EGP, independent of gut metabolism.
To determine whether portal vein-infused metformin suppresses hepatic gluconeogenesis in a substrate-specific manner, we again infused [3-13 C]alanine or [3-13 C]lactate tracers in the HFD-fed, STZ-treated (HFD-STZ) rats and measured the effect of portal vein metformin treatment on substrate turnover and clearance. Although portal infusion of metformin did not affect alanine turnover or alanine clearance rates (Fig. 5c,d) , lactate turnover and clearance (Fig. 5e,f) as well as β -hydroxybutyrate turnover (Fig. 5g ) were significantly lower with metformin treatment. Finally, using the [1,1,2,3,3-2 H 5 ]glycerol tracer, we determined that portal vein delivery of metformin led to significantly lower glycerol turnover and glycerol clearance (Fig. 5h,i) . These redox-dependent, substrate-specific effects of metformin on lactate and glycerol turnover and clearance rates were independent of changes in hepatic energy charge (reflected by the absence of changes in [ATP]:[ADP] and [ATP]:[AMP] ratios) ( Supplementary Fig. 8a,b) , AMPK activation and ACC phosphorylation ( Supplementary Fig. 8c,d ) and CREB phosphorylation ( Supplementary Fig. 8e ). The expression of hepatic PC protein remained unaltered, whereas expression of PEPCK-C protein was slightly increased ( Supplementary Fig. 8f,g) . Finally, using positional isotopomer NMR tracer analysis (PINTA) to noninvasively evaluate hepatic mitochondrial metabolism, we determined that portal vein metformin infusion inhibited flux through hepatic pyruvate carboxylase (V PC ) by approximately 30% (Fig. 5j ). However, there was no impact on hepatic citrate synthase flux rates (V CS ; Fig. 5k ), which would be predicted to decrease if metformin was causing significant inhibition of complex I activity.
Chronic oral metformin treatment decreases plasma glucose concentration and inhibits EGP in ZDF and HFD-STZ rat models of T2D. Though we were able to demonstrate that i.v. and intraportal delivery of metformin acutely decreased rates of hepatic gluconeogenesis by increasing the cytosolic redox state, we next wanted to examine whether this also occurred in a more clinically relevant context where metformin was administered orally in two well-established rat models of T2D. First, we treated ZDF rats with an upward titration of metformin dose, to mimic what is typically done in the clinic, in drinking water at 0.5 mg mL -1 for 7 d, 1.8 mg mL -1 for 7 d and finally 2.7 mg mL -1 for 14 d (final chronic dose, 200-300 mg kg -1 per day). This upward oral metformin titration regimen led to clinically relevant plasma metformin concentrations of ~15 μ M and hepatic metformin concentrations of ~40 μ M ( Supplementary  Fig. 9a,b ) resulting in reductions in fasting plasma glucose concentrations of > 100 md dL -1 ( Supplementary Fig. 9c ). Neither liver citrate nor succinate concentrations were altered with metformin treatment, suggesting that complex I and complex II inhibition were not primarily responsible for metformin's therapeutic actions under these conditions ( Supplementary Fig. 9d,e ). However, similar to what was observed in the acute jugular and portal vein metformin infusion studies, chronic oral metformin treatment resulted in elevated hepatic G-3-P concentrations ( Supplementary Fig. 9f ). EGP was significantly inhibited by chronic oral metformin treatment ( Supplementary Fig. 9g ), and this effect was independent of changes in hepatic nucleotide concentrations ( Supplementary  Fig. 9h ), AMPK or ACC phosphorylation ( Supplementary Fig. 9i ,j) and dissociated from changes in gluconeogenic enzyme protein expression ( Supplementary Fig. 9k-n) .
We then conducted a chronic, oral metformin treatment study in a second rat model of T2D, the HFD-STZ rats, and performed [3-13 C]lactate and [3-13 C]alanine tracer infusions to evaluate the effect of chronic metformin treatment on substrate-specific contributions to hepatic gluconeogenesis. HFD-STZ rats were treated with metformin in drinking water (3.5 mg mL -1 ) over 14 d, achieving hepatic metformin concentrations of ~15 μ M ( Supplementary  Fig. 10a ). Fasting plasma glucose concentrations were significantly lower with chronic oral metformin treatment in both [3-13 C]lactate-and [3-13 C]alanine-infused cohorts of HFD-STZ rats in the tracer-infusion studies (Fig. 6a ). Hepatic cytosolic redox state was increased with chronic oral metformin treatment, as determined by an increased [lactate]:[pyruvate] ratio ( Fig. 6b and Supplementary  Fig. 10b,c) . Consistent with all of the other parenterally and orally administered metformin studies, hepatic G-3-P concentrations were increased with chronic oral metformin treatment (Fig. 6c) , and EGP was inhibited by metformin in both tracer-infusion cohorts (Fig. 6d ).
Using PINTA, we were able to determine that V PC (Fig. 6e ) was significantly decreased with chronic oral metformin treatment.
However, consistent with the prior portal vein metformin treatment study, there was no impact on V CS (Fig. 6f ), suggesting again that complex I inhibition is not the central mechanism of metformin action at clinically relevant liver metformin concentrations, even in chronically treated diabetic rats. As observed in all of our other studies, we found that oral metformin treatment inhibited the contributions of [3-13 C]lactate to hepatic gluconeogenesis but had no effect on contributions of [3-13 C]alanine to gluconeogenesis in this diabetic rat model ( Fig. 6g and Supplementary Fig. 10d ). Metformin's impact on glycemia, hepatic gluconeogenesis and specific contributions of [3-13 C]lactate to gluconeogenesis were all independent of major changes in hepatic nucleotide concentrations ( Supplementary Fig.  10e,f 
), as both [ATP]:[ADP] and [ATP]:
[AMP] ratios were slightly increased in metformin-treated rats. Phosphorylation of AMPK and ACC were not increased ( Supplementary Fig. 11a,b) , and though CREB phosphorylation was decreased, the protein expression levels of gluconeogenic enzymes (G6Pase, PC and PEPCK-C) were all unchanged ( Supplementary Fig. 11c-f ). These data further support the hypothesis that redox modulation remains the relevant mechanism of metformin action in a context that better mimics the pharmacokinetics of metformin-treated individuals with T2D.
Discussion
Several molecular mechanisms have been proposed to be metformin's mode of action. Though metformin does inhibit complex I activity, this effect has only been observed at millimolar concentrations of the drug 1,2 and is therefore unlikely to be clinically relevant given that plasma concentrations in metformin-treated individuals with T2D are typically in the 8-24 μ M range 26, 48 , comparable to concentrations observed in this study. Furthermore, the ability of metformin to lower plasma glucose concentrations independently of the AMPK-ACC axis has been established, indicating that although AMPK activation and ACC inhibition may contribute to some of the beneficial effects of chronic metformin treatment 5 , the fundamental mechanism through which metformin inhibits hepatic gluconeogenesis does not require AMPK activation and/or ACC1 and ACC2 inhibition. This is consistent with the inability of metformin to reverse NAFLD in individuals with T2D in the absence of weight loss 49, 50 in contrast to the ability of ACC inhibitors to decrease hepatic steatosis in individuals with NAFLD 51 .
An additional molecular target implicated in metformin action is adenylate cyclase, posited to be allosterically inhibited by increased [AMP] provoked by metformin. The resulting decrease in cAMP production would position metformin as an effective inhibitor of glucagon-stimulated hepatic gluconeogenesis. However, a recent study has demonstrated that metformin does not impact glucagonstimulated gluconeogenesis in prediabetic individuals 52 , suggesting that modulation of cAMP or cAMP-regulated gene expression does not explain metformin's therapeutic benefits in humans. The fact that modulation of cAMP-regulated gene expression is not essential to metformin action is also demonstrated by our previous studies 15 as well as by our present findings showing no impact of acute or chronic metformin therapy on hepatic gluconeogenic enzyme protein expression in normal and T2D rats. Additionally, although acute metformin treatment in normal SD rats and both acute and chronic metformin treatment in two rat models of T2D inhibited hepatic gluconeogenesis, these therapeutic effects were not concomitant with AMPK activation, ACC phosphorylation, alterations in hepatic mitochondrial citrate synthase flux or altered liver triglyceride content. However, the redox state was consistently altered in tandem with any acute changes in plasma glucose and hepatic gluconeogenic rates in all three animal models, a phenomenon reaffirming what we saw in our previous metformin treatment studies 15 . These data suggest that previously described mechanisms of metformin action invoking complex I, AMPK-mediated ACC phosphorylation or decreased ectopic lipid accumulation in liver do not play a major role in the metformin's ability to acutely decrease hepatic gluconeogenesis at clinically relevant doses in vivo.
The redox-dependent, substrate-selective inhibition of gluconeogenesis observed in vivo with metformin treatment is consistent with the hypothesis that metformin inhibits GPD2 activity, either through direct and/or indirect mechanisms involving regulatory cofactors, increasing the hepatic cytosolic redox state and preventing lactate conversion to pyruvate and G-3-P conversion to dihydroxyacetone phosphate (DHAP). These substrate-specific effects would not be predicted by metformin inhibition of hepatic mitochondrial complex I activity, charges in hepatic [ATP], [ADP] or [AMP], hepatic gluconeogenic transcriptional regulation or AMPK activation. Metformin-induced increases in the hepatic cytosolic redox state have been demonstrated independently, both during acute intravenous and chronic oral metformin treatment increasing the liver [lactate]:[pyruvate] ratio and plasma lactate concentration without any effect on hepatic mitochondrial oxidative metabolism. Corroborating these data and the present findings are recent studies using hyperpolarized magnetic resonance spectroscopy, which demonstrate that 50 mg kg -1 i.v. metformin acutely increases cytosolic redox state in rat kidney, liver and heart 53, 54 . Indeed, metformin-mediated increases in plasma lactate and the [lactate]:[pyruvate] ratio in humans have also been observed and underscore the clinical significance of a redox-based mechanism of action for metformin 55, 56 . Numerous studies have established the importance of α -glycerophosphate shuttling in the modulation of gluconeogenic rates, showing that high protein and activity levels of hepatic GPD2 cause increased hepatic glucose production, and low hepatic GPD2 activity leads to diminished hepatic gluconeogenesis [57] [58] [59] . Our previous work revealed that GPD2 is a key target of metformin action; however, the current in vivo carbon flux analysis demonstrates that redox-modulation by metformin is a key element required to establish the physiological relevance of this mechanism of action. Here we show that metformin inhibits hepatic gluconeogenesis in vivo at clinically relevant plasma and liver concentrations in a substrate-selective manner that is redox dependent and that would not be predicted by any other proposed mechanism 2,4-15 . This redox-dependent mechanism would also explain why metformin treatment is rarely associated with hypoglycemia given that gluconeogenesis will never be totally inhibited. Studying the impact of acute i.v. or intraportal infusion and chronic oral metformin treatment on carbon fluxes provided the added advantage of delineating the central, therapeutically relevant target of metformin action while minimizing potential suprapharmacological effects of metformin (e.g., complex I inhibition, complex II inhibition, complex IV inhibition, etc.) 1,2,11,60 that are not likely to be clinically relevant 48 . Taken together, results from these studies demonstrate that metformin, at clinically relevant plasma concentrations, inhibits hepatic gluconeogenesis in a redox-dependent manner independent of reductions in citrate synthase flux, hepatic nucleotide concentrations, acetyl CoA carboxylase activity or hepatic gluconeogenic protein expression.
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41591-018-0125-4.
Hepatocyte studies. Primary hepatocytes were isolated from 24-h-fasted SD rats and treated with or without 100 μ M metformin, 300 μ M 3-mercaptopicolinic acid or 4 mM phenylacetate in DMEM supplemented with 10 mM substrate (glycerol at 100 μ M). Glucose was measured using the Genzyme Glucose-SL reagent.
Human metformin pharmacokinetic studies. The human metformin acute dosing pharmacokinetic study was reviewed and approved by the Yale Human Investigation Committee, and written informed consent was obtained from each participant after explanation of the purpose, nature and potential complications of the study. The study was performed according to the ethical guidelines and regulations as determined by the Yale Human Investigation Committee. Plasma metformin concentrations were measured every 10 min in three subjects with T2D following an oral dose of 1 g metformin, and in subject with T2D on chronic metformin treatment (1 g per os (p.o.) twice per day). Plasma metformin concentrations were measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS) as previously described 2 .
Animal studies. Studies were performed in awake, unrestrained male rats. SD and ZDF rats were acquired from Charles River and were administered regular chow and water ad libitum. T2D was induced in SD rats through feeding with a safflower oil-based high-fat diet (Dyets, Inc. no. 112245) for 4 weeks, then treating rats with nicotinamide (80 mg kg -1 ) and, 15 min later, with low-dose STZ (45 mg kg -1 )-the HFD-STZ rat model of T2D 61 . Overnight-fasted rats with plasma glucose concentrations > 300 mg dL -1 or plasma insulin < 20 μ U mL -1 , indicating severe insulinopenia (type 1 diabetic rodent model), were excluded from analysis. Rats were individually housed and were subjected to a 12 -h light and 12-h dark cycle. Arterial lines were surgically implanted into the carotid artery and venous lines into the jugular vein of rats for the studies. A subset of rats underwent surgery to place catheters in the portal vein, carotid artery and jugular vein. All animal studies included 5-12 rats per group that were 9-12 weeks of age and that weighed 300-450 g at the time of study, except for the portal vein studies, in which rats weighed 400-600 g. Animals were randomly allocated to treatment groups before collection of any data (for example, weight) or surgical procedures, and the studies were performed without blinding. Sample sizes were selected to detect moderate to large (> 20%) differences. All studies were performed in awake, unrestrained animals. For acute administration, 50 mg kg -1 metformin was administered either intravenously (i.v.) in 0.9% saline over 5 min, or 50 mg kg -1 metformin in saline was infused via portal vein over 10 s. Unless otherwise stated, rats were fasted for 24 h before studies were conducted. At the conclusion of all in vivo studies, rats were anesthetized by i.v.-administered pentobarbital. For studies of chronic treatment with metformin administered orally, rats were given ad libitum access to drinking water with metformin or untreated drinking water (control group). The metformin concentration in drinking water was determined on a per-rat basis and adjusted twice-weekly on the basis of measured daily water intake and body weight. For ZDF rats, the metformin dose in the drinking water was uptitrated on a weekly basis until a glucose-lowering dose was found: the initial dose was 0.5 mg mL -1 for 1 week, which was increased to 1.8 mg mL -1 for 1 subsequent week and then to 2.7 mg mL -1 for 2 subsequent weeks. ZDF rats were treated for a total of 4 weeks. For HFD-STZ SD rats, metformin was administered at 3.5 mg mL -1 throughout the 2-week study.
In the acute IV metformin studies in SD and ZDF rats, contributions of lactate and alanine to hepatic gluconeogenesis were measured by continuous [3-3 H] glucose tracer infusion at 0.1 μ Ci min -1 and [3-13 C]lactate or [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] C]alanine at 40 μ mol kg body weight -1 min -1 (μ mol kg -1 min -1 ) for 120 min following a 5 min 120 μ mol kg -1 min -1 prime. In the chronic oral metformin study in HFD-STZ rats, substrate contribution to hepatic gluconeogenesis was measured by continuous [ 3 H]glucose tracer infusion at 0.1 μ Ci min -1 and [3-13 C]lactate or [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] C]alanine at 10 μ mol kg -1 min -1 for 120 min following a 5-min 30 μ mol kg -1 min -1 prime. Positional isotopomer NMR tracer analysis (PINTA) was used to noninvasively evaluate hepatic mitochondrial metabolism 62 . Label in hepatic lactate, alanine and glucose was assessed using nuclear magnetic resonance (NMR) spectroscopy and gas chromatography-mass spectrometry (GC-MS) as previously described 63 . Briefly, ~4-6 g ground liver samples were extracted for NMR in ~30 mL 7% perchloric acid. The pH of the supernatant was adjusted to 6.5-7.5 using 30% potassium hydroxide and was lyophilized. Extract was resuspended in 800 μ L potassium phosphate buffer: 2.4 mM NaCOOH, 30 mM K 2 HPO 4 , 10 mM KH 2 PO 4 and 20 mM DMSO in 100% D 2 O. 13 C NMR spectra were collected using the AVANCE 14 500-MHz NMR spectrometer (Bruker Instruments). Total glucose enrichment in the NMR extracts was determined by treating the extracts with methanol, drying them overnight and derivitizing them with 1:1 acetic anhydride:pyridine. The total [1-13 C], [2-13 C] , [5-13 C] and [6-13 C] enrichments were measured by GC-MS. The 13 C NMR spectra were used to determine relative positional enrichments of [ 13 C]glucose 62 . Enrichment of the 2 and 3 positions of alanine or lactate from [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] C]lactate or [3-13 C]alanine tracer was measured by proton-observed, carbon-edited (POCE) NMR 64 .
For the lactate and β -OHB turnover studies using the type 2 diabetes rat model (HFD fed, partial β -cell ablation), rats underwent a continuous arterial infusion with [3-13 C]lactate (Sigma), [1,2,3,4,5,6,6-2 H 7 ]glucose and [ 13 C 4 ]sodium β -hydroxybutyrate after a prime. The prime was 3 × the continuous rates for 5 min, followed by continuous tracer infusion at 10 μ mol kg -1 min -1 [3-13 C]lactate, 0.1 μ mol kg -1 min -1 [1,2,3,4,5,6,6-2 H 7 ]glucose, and 0.1 μ mol kg -1 min -1 [ 13 C 4 ] sodium β -hydroxybutyrate for 120 min. For alanine and glycerol turnover, rats were primed for five minutes at 3 × the continuous rates and then continuously infused for 120 min with tracer as follows: 10 μ mol kg -1 min -1 [3-13 C]alanine, 0.1 μ Ci min -1 [3-3 H]glucose, and 0.1 mg kg -1 min -1 [1,1,2,3,3 2 H 5 ]glycerol. Rats were infused at this rate for another 120 min after acute portal vein infusion of 50 mg kg -1 metformin to measure metformin-mediated alteration of turnover rates. Blood was sampled at 2 h and 4 h, and tissues were acquired by rapid freeze-clamp within 10 s of euthanization.
β -OHB and glycerol turnover were measured as we have described 65 . Lactate turnover was measured by GC-MS using the same derivatization protocol as was employed to measure β -OHB enrichment. Plasma β -OHB and lactate concentrations were measured by cobas, and plasma glycerol was measured by GC-MS. Clearance of each substrate was calculated as the ratio of the turnover rate divided by the plasma concentration.
EGP during the substrate infusion and MB studies was measured using continuous 1 mg kg -1 min -1 arterial infusion of [6,6-2 H 2 ]glucose following a 5 min 3 mg kg -1 min -1 prime. Rats were treated with an acute 2 mg kg -1 i.v. bolus of MB within the first 5 min of the study. Pyruvate or lactate was infused at 20 μ mol kg -1 min -1 , and DHA or glycerol was infused at 10 μ mol kg -1 min -1 throughout the course of the study (120 min). Plasma glucose was measured on the YSI 2700 Biochemistry Analyzer from sampled venous blood.
Whole-body ACC DKI mice were generated by Ozgene (Perth Australia) 5 . Catheters were surgically implanted into the jugular vein of mice 5-7 d before performing glucose infusion studies as previously described 66 . Mice were fasted overnight before the studies and were infused with [3-3 H]glucose at a rate of 0.05 μ Ci min -1 for 120 min to measure basal glucose turnover. Mice were then given acute metformin (50 mg kg -1 , i.v.) with continued [3-3 H]glucose infusion for another 120 min to measure metformin's effects on glucose turnover. Mice were restrained during the studies. Tissues were rapidly acquired and freeze-clamped within 10 s of euthanization.
All studies involving animals were conducted with prior approval from the Yale University Institutional Animal Care and Use Committee (IACUC) in compliance with the ethical standards outlined by the IACUC.
Metabolite measurement. Plasma glucose was measured on the YSI 2700 Biochemistry Analyzer. Surrogate metabolites for redox ratios were measured using enzymatic methods and by measuring NADH absorbance at 340 nm. Spectrophotometric measurements were made using the Flexstation 3 Benchtop Multi-Mode Microplate Reader (Molecular Devices). Liver metabolites were measured from PCA-extracted samples immediately after collection. Plasma glycerol was measured from deproteinized plasma samples derivitized with acetic anhydride and pyridine. Glycerol was measured by GC-MS using an added internal standard, [2-13 C]glycerol. Hepatic glycogen content was assessed by amyloglucosidase digestion as previously described 67 . Liver triglycerides were measured as previously described 68 . Liver lactate was measured from samples extracted by methanol:water (1:1 vol/vol ratio) on the YSI 2700 Biochemistry Analyzer. Hepatic G-3-P was measured by LC-MS/MS. Liver glycogen was measured by hydrolysis of glycogen and measure of glucose on the YSI 2700 Biochemistry Analyzer.
GC-MS analysis of pyruvate. For measurement of liver pyruvate, liver samples (100-150 mg) were homogenized together with 4% o-phenylenediamine in 4 N HCl solution, 16% sulfosalicilic acid (at a 1:1 vol/vol ratio) and α -ketoglutaric acid-d3 (internal standard). After centrifugation at 4,000 r.p.m. for 10 min, the supernatant was heated for 45 min at 90 °C to complete o-phenylene-diamine derivatization. After cooling, the samples were extracted twice with ethyl acetate, dried under nitrogen and further derivatized with N,O-Bis(trimethylsilyl)trifluoroacetamide (BSTFA) + 1% trimethylchlorosilane (TMCS) and pyridine (volume ratio of 1:1, 30 min at 45 °C then overnight at room temperature). Samples were analyzed using GC-MS (Agilent G1530A-5975C) with MS analysis in chemical ionization (CI) mode using isobutane as the reagent gas, and the GC was equipped with an HP-1 capillary column (25 m × 0.2 mm ID, 0.33μ m film thickness). The column temperature was initially held at 150 °C for 1 min, then ramped up 15 °C per minute to 220 °C for a final hold time of 3 min. Data was recorded in selected ion monitoring (SIM) mode for pyruvate ions m/z 233-237 (retention time (RT) = 4.0 min) and α -ketoglutaric acid-d3 ion m/z 278 (RT = 5.1 min).
LC-MS/MS quantitation of citrate and succinate.
Frozen tissue (~100 mg) was weighed in a 2.0-mL microcentrifuge tube, and then 1.5 mL of prechilled methanol/water (50:50 vol/vol) solution containing 0.1 µ mol of the internal standards ([ 13 C 6 ]citric acid and [ 13 C 4 ]succinic acid) was added, which was followed by disruption at 30 Hz for 2.0 min (Qiagen Tissue Lyser) and centrifugation (4,000 r.p.m.) at 4 °C for 10 min. The supernatant was filtered with a nanosep 100 K centrifugal device (Pall Life Science) before LC-MS/MS analysis. LC-MS/ MS analysis was performed on an Applied Biosystems 6500 QTRAP (Foster City, CA) equipped with a Shimadzu ultrafast liquid chromatography (UFLC)
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Data collection
No software was used for data collection.
Data analysis
Microsoft Excel for Mac 2011, version 14.1.0, and Graphpad Prism 7 for Mac OS X were used to perform the data analyses and statistical analyses for this study.
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Cell line source(s)
Primary hepatocytes isolated from rat livers were used, but no established cell lines were used in this study.
Authentication
Primary hepatocytes studied were determined viable if glucose production in response to pyruvate substrate was observed, and if the general cell morphology was intact. Cells were only plated if the preparation was at least 90% viable (less than 10% cell death).
Mycoplasma contamination
Cell preparations were not tested. 
Commonly misidentified lines

Wild animals
The study did not involve wild animals.
Field-collected samples
The study did not involve samples collected in the field.
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Population characteristics
The human metformin acute pharmacokinetic study was reviewed and approved by the Yale Human Investigation Committee and written informed consent was obtained from each participant after explanation of the purpose, nature, and potential complications of the study. Plasma metformin concentrations were measured every 10 min in three type 2 diabetic subjects following a single oral 1 g dose of metformin, and in one type 2 diabetic subject taking chronic metformin treatment (1g p.o. twice a day). Plasma metformin concentrations were measured by LC-tandem mass spectrometry as previously described (16) .
Recruitment
Patients with type 2 diabetes were recruited from the local community by poster advertisement.
